Fluticasone Furoate
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
Fluticasone Furoate: From Asthma and Allergic Rhinitis to Atopic Eczema
One-Sentence Summary
Fluticasone furoate is a corticosteroid originally used for asthma and allergic rhinitis. The TxGNN model predicts it may be effective for atopic eczema, but there are currently 0 clinical trials and only 2 loosely related publications (a review and a case report), so this is a model prediction without direct supporting evidence.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Asthma, allergic asthma, allergic rhinitis, vasomotor rhinitis (the Singapore licence records do not state an approved indication text) |
| Predicted New Indication | Atopic eczema |
| TxGNN Prediction Score | 99.98% |
| Evidence Level | L5 |
| Singapore Market Status | ✓ Marketed |
| Number of Registrations | 3 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available in the compiled record. Fluticasone furoate is a potent glucocorticoid receptor agonist. Corticosteroids suppress inflammatory signalling, and topical corticosteroids are a standard anti-inflammatory approach in atopic eczema.
Asthma, allergic rhinitis and atopic eczema are closely related allergic (atopic) conditions that often occur together in the same patient. This shared inflammatory background is a plausible reason the model links the drug to atopic eczema.
However, the two publications retrieved do not test fluticasone furoate in eczema. One concerns adrenal suppression with intranasal corticosteroids, and the other concerns allergen immunotherapy in a patient with autoimmune disease. The very high prediction score therefore remains a model output, not clinical proof. In addition, the licensed Singapore products are a nasal spray and inhaled powders, not a skin formulation.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 19571596 | 2009 | Review | Neuroimmunomodulation | Allergic rhinitis often coexists with asthma and atopic dermatitis. Reviews how intranasal corticosteroids may suppress the adrenal (HPA) axis and how best to detect this. It does not test efficacy in eczema. |
| 40066386 | 2025 | Case report | Indian J Otolaryngol Head Neck Surg | Discusses allergen immunotherapy in patients with autoimmune disease, mentioning atopic dermatitis only as an emerging application. It does not involve fluticasone furoate. |
Singapore Market Information
| Authorization Number | Product Name | Dosage Form |
|---|---|---|
| SIN13666P | Avamys Nasal Spray 27.5 mcg/spray | Suspension spray |
| SIN15806P | Trelegy Ellipta Inhalation Powder 100/62.5/25 mcg | Metered powder |
| SIN16914P | Trelegy Ellipta Inhalation Powder 200/62.5/25 mcg | Metered powder |
All three licences are currently valid. None is for a skin (topical) formulation.
Safety Considerations
- Contraindication associations (from drug-disease relationships compiled for this report, not package insert text): measles, herpes simplex keratitis, varicella zoster infection, fungal infection, dermatophytosis, pulmonary tuberculosis, parasitic and other infectious diseases, adrenocortical insufficiency, Addison disease, adrenal gland hyperfunction, Cushing syndrome, ocular hypertension, glaucoma, and diseases of the nasal cavity, paranasal sinuses, and upper and lower respiratory tract.
- Adrenal suppression: The retrieved review highlights that intranasal corticosteroids can affect the HPA axis, which is relevant to any new use involving long-term or wider-area exposure.
Please refer to the package insert for full warnings, contraindications and drug interaction information.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction score is very high, but there are no clinical trials and no literature testing fluticasone furoate in atopic eczema. The approved Singapore products are nasal and inhaled forms, so a new topical product would be needed. The corticosteroid mechanism is plausible, but the evidence is prediction only.
To proceed, the following is needed:
- Clinical or preclinical studies of fluticasone furoate (ideally in a topical formulation) in atopic eczema
- A comparison with existing topical corticosteroids already standard for eczema
- Package insert warnings and contraindications for Singapore products
- Detailed mechanism of action data
- A route and formulation assessment, including systemic exposure and adrenal suppression risk
Note on other predictions: Among the other predicted indications, only obstructive lung disease (including COPD) has substantial support, including several Phase 3 trials and large RCTs of fluticasone furoate combination inhalers. This is closely related to the existing asthma use rather than a novel repurposing, and it would warrant "Proceed with Guardrails" in its own right. The evidence is for fixed-dose combinations rather than monotherapy, and the pneumonia risk of inhaled corticosteroids in COPD needs managing through patient selection.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.